Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study

Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study

Background: The advent of monoclonal antibodies (mAbs) has revolutionized the management of many immune-mediated diseases such as inflammatory bowel disease (IBD). Infliximab and adalimumab were the first mAbs approved for the management of IBD, and are still commonly prescribed for the treatment of...

Full description

Bibliographic Details
Main Authors: Othman Alharbi, Abdulrahman M. Aljebreen, Nahla A. Azzam, Majid A. Almadi, Maria Saeed, Baraa HajkhderMullaissa, Hassan Asiri, Abdullah Almutairi, Yazed AlRuthia
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Journal of Clinical Medicine
Subjects:
inflammatory bowel disease
infliximab
adalimumab
Crohn’s disease
ulcerative colitis
biologic failure
Online Access:https://www.mdpi.com/2077-0383/11/14/4157

Internet

https://www.mdpi.com/2077-0383/11/14/4157

Similar Items